Overall verdict
Neutral
5.6/10
1-year performance
+19.06%
Score breakdown
Up 19.1% over 1 year, 96% of the 52-week range.
Strongest: Profitability 7.5/10. Weakest: Shareholder return 0.7/10.
24 analysts, target +0.1% vs the price.
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms.
Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Six
Switzerland
CEO
Dr. Wolfgang Wienand Ph.D.
Founded
1897
Employees
16 866
Revenue / employee
387 229 CHF
Next earnings
January 26, 2027 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
674.00 CHF
52-week low
454.60 CHF
1-year performance
19.06%
Rising
Year-to-date performance
25.00%
Rising
Drawdown
-1.19%
Near its high
Position in the 52-week range
96% of range
Range: 550.00 CHF - 638.09 CHF (2 methods agree)
The price implies growth of 37.16% per year; the company grows at 7.70%.
Gross margin 36.5%, the company loses 4.2% of its revenue, ROIC 8.7%, ROE 12.6%.
Net margin
-4.21%
Negative
Sector 3.88%|S&P 13.40%
Gross margin
36.53%
Fair
Return on equity (ROE)
12.64%
Exceptional
Sector 3.46%|S&P 17.06%
Return on invested capital (ROIC)
8.70%
Exceptional
Free cash flow margin (FCF)
3.40%
Low
Margin stability
14.4 pts
Very uneven
Revenue to net income
Growth
3.5/10Revenue up 11.2% over 1 year, 7.7% a year over 5.
Revenue (trailing 12 months)
6.2Md CHF
Revenue growth (1y)
11.20%
Strong
Revenue growth (3y)
4.95%
Moderate
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
1.04%
Revised up
Valuation
3.4/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 48.4x|S&P 23.6x
Forward P/E
38.6x
Expensive
EV / EBITDA
23.2x
Fair
Sector 22.9x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Fair value (reverse DCF)
594.04 CHF
Overvalued
Market cap
45.2Md CHF
Financial strength
6.9/10Cash covers 11.7% of the debt, net debt/EBITDA 1.9x.
Net debt / EBITDA
1.9x
Tight
Gearing (net debt / equity)
45.14%
Solid
Cash
478M CHF
Cash / market cap
1.06%
Stretched
Cash / total debt
11.69%
Stretched
Interest coverage
13.2x
Very solid
Net debt
3.6Md CHF
Equity
8.0Md CHF
Closed daily candles, 2 years
Last close on November 11, 2026: 663.60 CHF
- MM20639.84
- MM50592.78
- MM200541.87
- RSI 1472.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.71%
200-day average slope, 3 months
+2.71%
50-day average slope, 1 month
+4.43%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.03 % per day
Volatility change
-23.19%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 17.25 (19) | 18.70 (18) | 7 121 (22) | 2 383 (19) | 1 218 (16) |
| 2027 | 20.61 (18) | 22.44 (18) | 7 955 (22) | 2 721 (20) | 1 428 (15) |
Amounts in millions of CHF, EPS in CHF per share. In brackets, the number of analysts. Consensus as of November 6, 2026.
Same sub-industry: 104 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.7 | 8.2 | 68.4Md USD | — | — | 70.5 % | — | -1.7x | — | 62.1 % | ||
| 2 | IQV | 7.3 | 6.9 | 45.2Md USD | 33.4x | 8.1 % | 8.0 % | 6.8 % | 4.1x | 4.6 % | 28.0 % | ||
| 3 | A207940 | 7.1 | 7.0 | 52.5Md USD | 39.7x | 41.1 % | -10.2 % | — | -0.2x | — | -24.4 % | ||
| 4 | A | 6.5 | 6.0 | 49.9Md USD | 34.8x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.5 % | 20.4 % | ||
| 5 | DHR | 6.5 | 6.4 | 166Md USD | 38.5x | 16.7 % | 8.3 % | 5.9 % | 2.0x | 3.5 % | 11.5 % | ||
| 6 | TMO | 6.2 | 5.5 | 266Md USD | 37.9x | 14.9 % | 9.1 % | 8.0 % | 2.8x | 2.9 % | 24.6 % | ||
| 7 | LONN | 5.6 | 4.7 | 54.3Md USD | Not meaningful (loss) | -4.2 % | 11.2 % | 8.7 % | 1.9x | 0.5 % | 19.1 % | ||
| 8 | MTD | 5.3 | 4.9 | 34.8Md USD | 37.9x | 22.2 % | 6.3 % | 47.4 % | 1.8x | 2.5 % | 21.0 % | ||
| 9 | WAT | 4.3 | 1.7 | 46.3Md USD | 202.3x | 1.8 % | 120.9 % | 0.8 % | 0.8x | 0.6 % | 23.9 % |
